Effects of Tyroserleutide on phosphatidylinositol 3′-kinase/AKT pathway in human hepatocellular carcinoma cell

References

• Gentilucci L, Tolomelli A, Squassabia F. Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr Med Chem 2006;13:2449–66
   PubMed Web of Science ®Google Scholar
• Los M, Burek CJ, Stroh C, et al. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov Today 2003;8:67–77
   PubMed Web of Science ®Google Scholar
• Johar D, Roth JC, Bay GH, et al. Inflammatory response, reactive oxygen species, programmed (necrotic-like and apoptotic) cell death and cancer. Rocz Akad Med Bialymst 2004;49:31–9
   PubMedGoogle Scholar
• Fu Z, Lu R, Li G, et al. Tyroserleutide tripeptide affects calcium homeostasis of human hepatocarcinoma BEL-7402 cells. Sci China C Life Sci 2005;48:23–30
   Google Scholar
• Yao Z, Lu R, Jia J, et al. The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma. Peptides 2005;27:1167–72
   PubMed Web of Science ®Google Scholar
• Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999;253:210–29
   PubMed Web of Science ®Google Scholar
• Michl P, Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005;43:1133–9
   Google Scholar
• Khwaja A. Akt is more than just a Bad kinase. Nature 1999;401:3–4
   PubMed Web of Science ®Google Scholar
• Li XL, Liu JY, Lu R, et al. Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assay. Invest New Drugs 2008;26:525–9
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402–8
   PubMed Web of Science ®Google Scholar
• Park DJ, Patek PQ. Detergent and enzyme treatment of apoptotic cells for the observation of DNA fragmentation. Biotechniques 1998;24:558–60
   PubMed Web of Science ®Google Scholar
• Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003;115:145–67
   PubMedGoogle Scholar
• Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004;15:177–82
   PubMed Web of Science ®Google Scholar
• Konishi H, Kuroda S, Tanaka M, et al. Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun 1995;216:526–34
   PubMedGoogle Scholar
• Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999;9:125–8
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655–7
   PubMed Web of Science ®Google Scholar
• Casamayor A, Morrice NA, Alessi DR. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 1999;342:287–92
   PubMed Web of Science ®Google Scholar
• Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000;20:5010–18
   PubMed Web of Science ®Google Scholar
• Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187–98
   PubMed Web of Science ®Google Scholar
• Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis – the p53 network. J Cell Sci 2003;116:4077–85
   PubMed Web of Science ®Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–31
   PubMed Web of Science ®Google Scholar
• Zhou BP, Liao Y, Xia W, et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973–82
   PubMed Web of Science ®Google Scholar
• Dictor M, Ehinger M, Mertens F, et al. Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 1999;112:S40–52
   PubMed Web of Science ®Google Scholar
• Lu R, Jia J, Bao L, et al. Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide (YSL). Cancer Chemother Pharmacol 2006;57:248–56
   PubMed Web of Science ®Google Scholar
• del Peso L, González-García M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687–9
   PubMed Web of Science ®Google Scholar
• Hsu SY, Kaipia A, Zhu L, Hsueh AJ. Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11. Mol Endocrinol 1997;11:1858–67
   PubMed Web of Science ®Google Scholar
• Rong Y, Distelhorst CW. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu Rev Physiol 2008;70:73–91
   PubMed Web of Science ®Google Scholar
• Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37–43
   PubMed Web of Science ®Google Scholar
• Murphy KM, Ranganathan V, Farnsworth ML, et al. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ 2000;7:102–11
   PubMed Web of Science ®Google Scholar
• Minn AJ, Kettlun CS, Liang H, et al. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J 1999;18:632–43
   PubMed Web of Science ®Google Scholar
• Lemasters JJ, Theruvath TP, Zhong Z, Nieminen AL. Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta 2009;1787:1395–401
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39–51
   PubMed Web of Science ®Google Scholar
• Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805–16
   PubMed Web of Science ®Google Scholar
• Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136–44
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296–9
   PubMed Web of Science ®Google Scholar